Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

Intervenn Biosci

Other names: Intervenn Biosciences
Related tests:


InterVenn Biosciences announces new data validating the clinical performance of DAWN™ IO Melanoma as a novel liquid biopsy test to improve assessment of benefit to cancer patients (Businesswire)
"InterVenn® Biosciences...announced new data showing that its new DAWN IO Melanoma test accurately assesses and classifies advanced melanoma patients as likely or unlikely to benefit from immune checkpoint inhibitor therapies: either pembrolizumab alone or ipilimumab in combination with nivolumab."
Retrospective data
InterVenn Biosciences joins the WIN and FNIH Biomarker Consortiums to introduce a glycoproteomic option for liquid biopsies (Businesswire)
"InterVenn® Biosciences...announced that it has joined the Worldwide Innovative Network (WIN) Consortium and the Foundation for the National Institutes of Health’s Biomarker Consortium. InterVenn’s innovation in glycoproteomic-based liquid biopsies and translational research provides novel strategies and new tools to improve patient care, advance clinical trials, accelerate biomarker discovery, and enhance precision oncology."
Licensing / partnership
InterVenn to Present New Clinical Data at ASCO 2022 on Using Glycoproteomics as Powerful Liquid Biopsy Tests for Early Detection of Cancer and Prediction of Checkpoint Inhibitor Treatment Benefit (Businesswire)
"InterVenn Biosciences...today announced that it will present new clinical data detailing the success of its novel approach to liquid biopsy testing in multiple cancer indications at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. The meeting will take place from June 3 to June 7 at McCormick Place in Chicago....InterVenn will present two posters and five online publications highlighting data that demonstrate clinically relevant applications of its glycoproteomics-based biomarker signatures in a variety of cancers, including malignant melanoma, ovarian cancer, colorectal cancer, non-small-cell lung carcinoma, and bone and soft tissue sarcoma."
Clinical data
InterVenn Biosciences raises $201 million for AI-driven glycoproteomic platform, liquid-biopsy development (Businesswire)
"InterVenn Biosciences today announced the completion of a $201 million Series C financing...The proceeds from the financing will be used to accelerate development and commercialization of Dawn™, the company’s liquid biopsy assay for immune checkpoint inhibitor response prediction, and to expand the network of partners on the company’s AI-driven glycoproteomics platform."